Core Viewpoint - Codex-B (02487.HK) has received approval from the Hong Kong Department of Health for its topical finasteride spray, CU-40102, aimed at treating androgenetic alopecia, marking a significant advancement following its approval from the National Medical Products Administration of China [1] Group 1: Product Details - CU-40102 is a topical formulation that inhibits the conversion of testosterone to dihydrotestosterone in the scalp, providing a targeted treatment for androgenetic alopecia [1] - Unlike oral finasteride, CU-40102 allows for precise application on the scalp, potentially reducing systemic exposure to the drug [1] Group 2: Market Implications - The approval of CU-40102 is a crucial step for the company in the hair disease and care sector, indicating extensive commercialization preparations in China [1] - This approval is expected to enhance the international presence of CU-40102, expanding its market reach and benefiting more patients suffering from androgenetic alopecia [1]
科笛-B(02487.HK)：CU-40102(外用非那雄胺喷雾剂)获得香港卫生署上市批准